Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.70    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.10 (3.846%)
Market Cap: £2.78m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Board Updates

2 Jul 2020 10:42

RNS Number : 8591R
Litigation Capital Management Ltd
02 July 2020
 

2 July 2020

 

Litigation Capital Management Limited

(LCM or the Company)

 

Board Updates

 

Litigation Capital Management Limited (AIM:LIT), specialist alternate asset manager and a leading international provider of disputes financing solutions, provides the following update:

 

· LCM currently looking to expand the geographic market reach of its Non-Executive Directors in line with LCM's business plan

· Steve McLean steps down as non-executive director as part of this upcoming Board realignment

· Minor delays in the CEO relocating to London due to COVID-19

 

LCM is at an advanced stage in the search to add additional Non-Executive Directors (NED) to the Board. As the Company strengthens its market positioning in the Northern Hemisphere, including the UK and Europe, as well as transitioning its management to the London office, it looks to new NED appointments to bring significant experience in these markets. As part of this upcoming restructuring, Steve McLean has kindly agreed to resign his position on the board effective as at 30 June 2020.

 

Steve was appointed to LCM's board as a NED prior to the Company's IPO on the Australian Securities Exchange. Steve brought with him significant in-region equity capital markets experience and has been a very valuable member of LCM's board during the building of its business, particularly in the APAC region.

 

LCM expects to be in a position to make an announcement as to a new Non-Executive board member in the near future.

 

Jonathan Moulds, Chairman of LCM, commented: "Steve has been a strong supporter of LCM through two IPOs, one on the Australian Securities Exchange and then on the London Stock Exchange:AIM as a Non-Executive board member. As LCM's business expands into new global markets, it will benefit from board experience in those large economies. We will continue to have access to Steve and his experience was a long-term supporter of the business. I thank him for his significant contribution to the growth of LCM over a number of years"

 

Enquiries

 

Litigation Capital Management

c/o Alma PR 

Patrick Moloney, Chief Executive Officer

 

 

 

Canaccord (Nomad and Joint Broker) 

Tel: 020 7523 8000

Bobbie Hilliam

 

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 5970

David Anderson

 

 

 

Alma PR

Tel: 020 3405 0205

Rebecca Sanders-Hewett

LCM@almapr.co.uk

Justine James

 

David Ison

 

 

NOTES TO EDITORS

 

Litigation Capital Management (LCM) is a global provider of disputes finance which operates two business models. The first is direct investments made from LCM's permanent balance sheet capital and the second is fund and/or asset management. Under those two business models, LCM currently pursues three investment strategies: Single-case funding, Corporate portfolio funding and Acquisitions of claims. LCM generates its revenue from both its direct investments and also performance fees through asset management.

LCM has an unparalleled track record, driven by effective project selection, active project management and robust risk management.

 

Headquartered in Sydney, with offices in London, Singapore, Brisbane and Melbourne, LCM listed on AIM in December 2018, trading under the ticker LIT.

 

www.lcmfinance.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOASSUSUEESSEDW
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.